BACKGROUND: Prostate-specific membrane antigen (PSMA) is a cell surface enzyme that is highly expressed in prostate cancer (PCa) and is currently being extensively explored as a promising target for molecular imaging in a variety of clinical contexts. Novel antibody and small-molecule PSMA radiotracers labeled with a variety of radionuclides for positron emission tomography (PET) imaging applications have been developed and explored in recent studies. METHODS: A great deal of progress has been made in defining the clinical utility of this class of PET agents through predominantly small and retrospective clinical studies. The most compelling data to date has been in the setting of biochemically recurrent PCa, where PSMA-targeted radiotracers have been found to be superior to conventional imaging and other molecular imaging agents for the detection of locally recurrent and metastatic PCa. RESULTS: Early data, however, suggest that initial lymph node staging before definitive therapy in high-risk primary PCa patients may be limited, although intraoperative guidance may still hold promise. Other examples of potential promising applications for PSMA PET imaging include non-invasive characterization of primary PCa, staging and treatment planning for PSMA-targeted radiotherapeutics, and guidance of focal therapy for oligometastatic disease. CONCLUSIONS: However, all of these indications and applications for PCa PSMA PET imaging are still lacking and require large, prospective, systematic clinical trials for validation. Such validation trials are needed and hopefully will be forthcoming as the fields of molecular imaging, urology, radiation oncology and medical oncology continue to define and refine the utility of PSMA-targeted PET imaging to improve the management of PCa patients. ( 1 Traditional imaging methods in PCa-including magnetic resonance imaging (MRI) for primary disease and contrast-enhanced computed tomography (CECT) and technetium-99 m ( 99m Tc)-methylene diphosphonate bone scan (BS) for metastatic disease-have a number of significant limitations. These limitations have stimulated the development of new molecular imaging approaches that promise improved sensitivity and specificity for diagnostic imaging of PCa.
INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed noncutaneous cancer in men in the United States. 1 Traditional imaging methods in PCa-including magnetic resonance imaging (MRI) for primary disease and contrast-enhanced computed tomography (CECT) and technetium-99 m ( 99m Tc)-methylene diphosphonate bone scan (BS) for metastatic disease-have a number of significant limitations. These limitations have stimulated the development of new molecular imaging approaches that promise improved sensitivity and specificity for diagnostic imaging of PCa.
A particularly promising target for PCa molecular imaging is prostate-specific membrane antigen (PSMA), a homodimeric type II membrane metalloenzyme that functions as a glutamate carboxypeptidase/folate hydrolase and is overexpressed in PCa. 2 PSMA is expressed in the vast majority of PCa tissue specimens and its degree of expression correlates with a number of important metrics of PCa tumor aggressiveness including Gleason score, propensity to metastasize and the development of castration resistance. [3] [4] [5] [6] [7] [8] [9] The recognition of these features of PSMA lead to the development of the first molecular imaging agent for this target, the radiolabeled monoclonal antibody indium-111 ( 111 In)-capromab pendetide (ProstaScint), which can be imaged using single-photon emission computed tomography to anatomically localize foci of PCa. ProstaScint provided important proof-ofconcept information demonstrating the ability of PSMA-directed imaging to detect metastatic recurrent PCa, 10, 11 but ultimately suffered from intrinsic limitations regarding its targeting of an intracellular epitope of PSMA, less ideal imaging characteristics of the 111 In radionuclide labeling, and longer blood pool biodistribution inherent in an intact antibody imaging agent.
More recently, new PSMA-targeted imaging agents, including both new antibodies with improved imaging characteristics 12 and small-molecule inhibitors of PSMA, [13] [14] [15] have been developed and extensively studied. Many of these agents are labeled with radionuclide that allows for positron emission tomography (PET) imaging (for example, fluorine-18 ( 18 F), gallium-68 ( 68 Ga) and zirconium-89 ( 89 Zr)), a functional imaging technique that provides improved spatial resolution and easier quantitation compared with single-photon emission computed tomography. Important clinical questions in both primary and metastatic PCa have begun to be addressed with these agents, and in the following review we will highlight some of the most important accomplishments to date as well as remaining challenges. The subheadings within this review were arrived at by consensus of the authors as representing important clinical questions that remain to be answered in PCa imaging. The majority of references for this narrative review were found by searching Pubmed for 'PSMA' and 'PET' or 'positron emission tomography.' Additional references were also incorporated on the basis of individual author's experience in PSMAtargeted PCa imaging or related fields.
CONTEMPORARY AGENTS FOR PSMA-BASED PET IMAGING OF PCA Although there are newer PSMA-targeted imaging agents labeled with single-photon emitting radionuclides such as technetium-99 m ( 99m Tc) 16 and iodine-123 ( 123 I, (ref. 17)), herein we will focus on PET radiotracers.
The prototype for an external epitope-binding PSMA-targeted antibody is J591. This intact human monoclonal antibody has been extensively studied and is currently finding application in PET imaging when labeled with 89 Zr, 18 a PET radionuclide with a particularly long half-life of 78.4 h. Antibody-based agents typically have long circulatory times before achieving optimal tumor-tobackground levels, necessitating the use of such long-lived isotopes for PET imaging. The primary disadvantage of intact antibodies for PET is the need for imaging several days after injection, although smaller engineered antibody fragments are being investigated in an effort to reduce the time required from injection to imaging. 19 Small-molecule inhibitors of PSMA have significant pharmacokinetic advantages over antibody-based agents, generally allowing imaging within 1 h of radiotracer injection. The vast majority of available data on PSMA PET imaging with small molecules has been obtained with agents labeled with 68 Ga (for example, refs [20] [21] [22] . The most common of these compounds contains the heterobifunctional linker N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid moiety that chelates the 68 Ga radiometal and is conjugated through a linker with a urea that binds in the active site of PSMA ( Figure 1) ; this agent is often referred to in the literature as ' 68 Ga-PSMA' or ' 68 Ga-PSMA N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid' or more recently ' 68 Ga-PSMA-11,' although a number of other 68 Ga-labeled radiotracers have been reported that differ in the chelation moiety and/or the linker. 68 Ga is an attractive radionuclide for PET imaging applications because it is produced by a tabletop 68 Ge/ 68 Ga generator, whereas most nuclei that decay by positron emission require a cyclotron. For smaller hospitals or academic centers that cannot support the infrastructure necessary to operate a cyclotron, 68 Ga is particularly attractive.
Although not as extensively studied as the 68 Ga agents, 18 F-labeled inhibitors of PSMA have been reported and offer distinct advantages ( Figure 1 ; refs 23,24). 18 F-labeled agents offer largescale radiosynthesis that would allow for a high volume of patient studies and these compounds also have a long enough physical half-life (109 min) that they can be centrally produced and distributed to many sites using the infrastructure that already exists for distributing 18 F-fluorodeoxyglucose for clinical applications (for example, PETNET in the United States). 18 F has higher intrinsic PET spatial resolution than 68 Ga, especially in smaller lesions, due to its intrinsically shorter positron range and higher positron yield, which may potentially be an advantage for detection of small subcentimeter lymph node metastases, although this needs to be further assessed in upcoming clinical trials. 25 IMPLICATIONS OF PSMA IMAGING IN LOCAL PCA According to current guidelines, patients with localized PCa may be managed with a number of different treatment options including active surveillance, radical prostatectomy, external beam radiation therapy and brachytherapy. [26] [27] [28] The choice of treatment is in large part predicated on patient age, coexisting medical comorbidities and risk of cancer progression. For those patients at the lowest risk for cancer progression (that is, cT1c, Gleason 3+3 and PSA ⩽ 10 ng ml − 1 ) active surveillance is often advocated as to avoid the potential complications of treatment. In contrast, for patients with intermediate-or high-risk cancer, active treatment with surgery or radiation therapy with or without hormonal therapy is more commonly selected. Finally, in the setting of metastatic disease, patients are typically managed with systemic therapy only (albeit the paradigm in recent years is shifting toward multimodal therapy including both treatment to the primary tumor and metastatic sites). Given these very different therapeutic trajectories for patients newly diagnosed with localized PCa, we believe that new molecular imaging agents would be most useful for (1) the characterization of PCa as clinically insignificant (that is, no Gleason pattern 4 or 5) and appropriate for active surveillance, (2) accurate pre-operative/preradiotherapy initial staging to ensure that disease is confined to the prostate and (3) assessment of response to pre-radiation androgen deprivation therapy (ADT) in patient with high-risk and locally advanced PCa.
Primary PCa characterization As noted above, PSMA expression correlates with PCa tumor aggressiveness. As such, it might be expected that with a quantitative imaging modality such as PET, the degree of radiotracer uptake might predict tumor Gleason score. Indeed, studies with PSMA PET ligands in patients with primary PCa suggest that such a correlation does exist. A prospective study by Osborne et al. 29 reported on imaging with a 89 Zr-labeled derivative of the J591 antibody in 11 patients undergoing radical prostatectomy. The long half-life of 89 Zr allowed ex vivo microPET imaging of the prostatectomy specimens and correlation of ex vivo Urea Moiety that Targets the PSMA Active Site Figure 1 . Chemical structures of (a) 68 Ga-PSMA-HBED-CC, the most common 68 Ga-labeled PSMA radiotracer and two 18 F-labeled agents, (b) results with in vivo PET imaging and findings on pathology. The authors found that 89 Zr-J591 reliably identified the sites of primary PCa with sum Gleason scores 47 and that the amount of ex vivo radiotracer uptake in the sites of disease positively correlated with Gleason score.
A similar prospective pilot study by Rowe et al. 30 examined the 18 F-labeled small-molecule radiotracer 18 F-DCFBC in 13 patients with primary PCa planned for radical prostatectomy. High-volume Gleason 7 and higher disease was successfully imaged (Figure 2 ), although small-volume and Gleason 6 disease was not always appreciated. Furthermore, the uptake of the radiotracer on PET imaging demonstrated a moderately strong positive correlation with Gleason score (ρ-coefficient = 0.65). An additional observation in this trial showed that PSMA PET may be potentially able to discriminate clinically significant high-grade PCa from BPH. These two studies offer encouragement that clinically significant disease that would merit aggressive therapy with prostatectomy or radiotherapy might be non-invasively identified by PSMA-based PET imaging with high specificity. Larger prospective trials, however, are needed to confirm these initial studies.
Pre-operative/pre-radiotherapy staging As with any malignancy, accurate pretreatment initial staging is essential to guide appropriate therapy. Particularly, in those PCa patients with suspected clinically localized disease that has highrisk features (defined by the National Comprehensive Cancer Network as T3a disease and/or sum Gleason score 8-10 and/or serum PSA420 ng ml − 1 ), there is a significant probability of lymph node metastases that are occult on CECT. 31 Patients with intermediate-risk disease (which the National Comprehensive Cancer Network defines as T2b-T2c and/or sum Gleason score 7 and/or PSA 10-20 ng ml − 1 ) may also have extraprostatic involvement and are often imaged in an effort to preoperatively identify metastatic sites. Indeed, CECT and MRI are both limited primarily to determining lymph node involvement on the basis of the size, although ancillary characteristics such as hyperenhancement, rounded lymph node shape and hypercellularity as determined by restricted diffusion can also aid in determining the presence of lymph node metastases. 32 Molecular imaging agents that might identify lymph node involvement more accurately than CECT have the potential to improve the selection of patients that are appropriate for local therapy.
A recent retrospective study by Budaüs et al. evaluating the ability of 68 Ga-PSMA agents to identify lymph node metastases in a cohort of patients with high-risk primary PCa demonstrated a surprisingly low sensitivity of only 33% at the patient level. 33 The specificity characteristics of the radiotracer in this context were outstanding, with 100% of the lymph nodes preoperatively identified on PET being found to contain disease. In addition, a larger (130 patients) retrospective study of intermediate-to high-risk patients undergoing 68 Ga-PSMA imaging before prostatectomy continued to find limitations in patient-level sensitivity (65.9%), although the specificity was also remarkably high (98.9%). 34 For comparison, a meta-analysis of CECT and MRI detection of metastatic lymph nodes in primary PCa patients found similar sensitivities as 68 Ga-PSMA (42% for CECT and 39% for pelvic MRI), although these modalities were not as specific. 35 Given the otherwise promising results that have been reported for PSMA-based radiotracers in other PCa applications, the relatively low reported sensitivities has sparked a discussion in the literature 36, 37 in which the importance of well-designed prospective studies in homogeneous patient populations was emphasized as important before conclusions regarding a new imaging method could be drawn. We agree with this assertion, however, in our own group's experience with the radiotracer 18 F-DCFPyL in a prospective study of patients with National Comprehensive Cancer Network high-and very-high-risk (T3b-T4 and/or Gleason pattern 5 and/or 44 cores with sum Gleason score 8-10) PCa, we also have observed somewhat limited sensitivity for PSMA-based detection of lymph node metastases in the pre-operative setting ( Figure 3 , currently unpublished results).
Although data with diagnostic pre-operative imaging suggest limitations, a small well-done study of five patients injected with an 111 In-labeled PSMA ligand for radioguided lymphadenectomy 24 h before radical prostatectomy was more encouraging. In this study, the authors found that radioguided surgery with the use of a gamma probe more reliably identified small lymph node metastases than did 68 Ga-PSMA PET imaging in the same patient cohort. 38 Although this finding will need to be confirmed in a larger group of patients, it might suggest that intraoperative guidance with PSMA ligands could be the most important application of these agents in primary disease staging. PET/CT images through the pelvis at the level of the prostate in a patient with Gleason 4+5 = 9 PCa in the anterior apex (red arrowheads, maximum SUV 4.1 (lean body mass corrected)). In a small series of patients, the degree of uptake of this radiotracer was shown to positively correlate to Gleason score. 29 (c) Axial T2-weighted images demonstrate a correlating low-signal abnormality in the same location (red arrowheads). The apparent diffusion coefficient MRI sequence acquisition had a great deal of intrinsic noise in this case and was of limited diagnostic utility (not shown). CT, computed tomography; MRI, magnetic resonance imaging; PCa, prostate cancer; PET, positron emission tomography; SUV, standardized uptake value.
Assessment of response to pre-radiation ADT Patients with high-risk localized or locally advanced PCa treated with standard-of-care radiation and ADT have highly variable, responses. Better markers to stratify and also adapt treatment to these patients earlier during their treatment course are needed. It is now well recognized that androgen receptor (AR) signaling is critical for PCa tumor maintenance in both hormone therapy naive as well as the castration-resistant state. Recent pre-clinical data suggest that PSMA is regulated directly by the AR and may serve as a surrogate marker for AR signaling dynamics. 39 A quantitative, non-invasive method for PSMA detection and more importantly monitoring AR signaling dynamics in humans is not currently available. Development of PSMA PET imaging may allow for the selection of appropriate risk adaptive therapies and allow noninvasive functional assessment of AR signaling dynamics in living subjects. Multiple randomized trials have established the benefit of combined modality therapy with androgen deprivation and radiation for men with high-risk localized or locally advanced PCa. [40] [41] [42] [43] Animal studies have shown that radiation is most effective for tumor reduction in combination with ADT. [44] [45] [46] This would agree with the increasing clinical evidence showing that biochemical response to ADT, as measured by PSA immediately before radiation, rather than duration of ADT is the critical factor for determining the benefit of combined treatment of radiation and ADT. [47] [48] [49] [50] [51] Recent studies have demonstrated that for men with clinically localized, nonmetastatic PCa receiving ADT and dose-escalated radiation, attaining a pre-RT PSA of o 0.5 or ⩽ 0.3 ng ml − 1 after ADT, portends improved clinical outcomes, suggesting that the degree of suppression of AR signaling determines outcome in men treated with radiation. 52, 53 The ability to identify men at increased risk of death from PCa based on preradiation AR signaling would help the design of new clinical trials testing novel, more potent anti-androgen therapies, such as enzalutamide, 54 in combination with radiation to improve the outcome for men who are poor responders to current standard-ofcare ADT regimens. The differential sensitivity of intra-prostatic lesions to ADT might be explained by different levels of AR inhibition. Furthermore, because declines in serum PSA levels reflect an average across all lesions, it is not currently possible to determine whether AR inhibition varies at different sites. A solution to those limitations of serum PSA may be PMSA-targered PET that accurately measures intra-tumoral AR signaling. In collaboration with the National Cancer Institute and Johns Hopkins University, a clinical trial to assess this hypothesis using 18 F-DCFPyL PET/computed tomography (CT) in high-risk and locally advanced PCa patients (NCT02420977) is currently underway.
APPLICATIONS OF PSMA IMAGING IN RECURRENT AND SYSTEMIC PCA Biochemically recurrent PCa
The most extensively studied application of PSMA-based imaging in PCa is in the context of biochemical recurrence following failed local therapy (defined as a rise in serum PSA level of ⩾ 0.2 ng ml − 1 post radical prostatectomy, 55 and as a 2 ng ml − 1 rise above the PSA nadir post radiation 56, 57 ). By definition, these patients do not have evidence of metastatic disease visible on conventional imaging, so the choice of salvage treatment (for example, systemic therapy versus radiation therapy of the prostate bed) is often based on imperfect clinical parameters such as PSA doubling time. Although there is certainly evidence that empiric therapy has benefits and improves outcomes in selected patients with biochemical recurrence, 58 reliable imaging assessment and localization of the site of recurrent disease would potentially provide more appropriate guidance of treatment (Figure 4 ). These considerations point to a significant need for improved imaging techniques in the biochemically recurrent patient population.
A number of studies in biochemically recurrent PCa patients have been carried out with PSMA-targeted imaging, primarily using 68 Ga-PSMA ligands and with some studies including comparison with choline-based PET radiotracers. These studies are summarized in Table 1 . The two largest reported studies by Afshar-Oromieh A et al. 12 and Eiber M. et al. 22 included 319 and 248 patients, respectively, and both reported promising results. In the 319-patient study, 21 Afshar-Oromieh et al. retrospectively analyzed imaging from patients with recurrent PCa and found at least one lesion suggestive of PCa in 82.8% of cases. Lesion detection was positively correlated with serum PSA level (with presumed sensitivity for PSA values ⩽ 0.5 ng ml − 1 of 48.1%, and presumed sensitivity for PSA values 420.0 ng ml −1 of 100.0%) and the administration of androgen deprivation therapy, but was not correlated with Gleason score at original diagnosis or serum PSA doubling time. In a subset of lesions for which histology was available, the true sensitivity was 76.6% with a specificity of 100.0%.
In the second large retrospective study, 22 Eiber et al. evaluated the results of 68 Ga-PSMA imaging in 248 patients with biochemical recurrence after radical prostatectomy. The detection rates were similar to the study by Afshar-Oromieh et al., 21 with 89.5% of patients demonstrating suspicious abnormal radiotracer uptake. The authors also found positive correlation with serum PSA levels, with detection rates ranging from 57.9% in patients with serum PSA 0.2 to o0.5 ng ml − 1 to 96.8% in patients with PSA42 ng ml − 1 . Higher PSA velocities did increase the detection rate; however, there was no significant correlation with PSA , Gleason 3+5 = 8) and no definitive evidence of pelvic lymph node metastases on CECT. Red arrowheads indicate intense radiotracer uptake in a 6-mm short axis diameter left external iliac lymph node that was subsequently proven to be disease involved following radical prostatectomy and pelvic lymph node dissection. The patient's primary disease was also radiotracer-avid but is below the level of this image. At midline, a large amount of radioactivity is present within the urinary bladder lumen. CECT, contrast-enhanced computed tomography; CT, computed tomography; NCCN, National Comprehensive Cancer Network; PCa, prostate cancer; PET, positron emission tomography.
doubling time. Interestingly, the Eiber et al. study differed in that higher Gleason score at the time of prostatectomy contributed to increased detection efficiency. Further, the authors reported no significant correlation between putative sensitivity and androgen deprivation therapy. These differences between these two large retrospective studies emphasize the need for well-designed prospective studies with large numbers of patients to deconvolute the nuances of PSMA PET utility and application in PCa biochemical recurrence.
An early study comparing a 68 Ga-labeled PSMA ligand to 18 F-fluoromethylcholine in the detection of biochemically recurrent PCa found a higher sensitivity for lesions typical of PCa with the PSMA-targeted radiotracer (86% of patients versus 70%, respectively 59 ). In another very well-done comparison with 18 Ffluoromethylcholine, the 68 Ga-labeled PSMA radiotracer prospectively detected lesions in 66% of 38 patients who had undergone prior attempt at curative therapy and then developed a posttherapy rise in PSA, whereas 18 F-fluoromethylcholine was putatively true positive in only 29% of patients. 60 The superiority of the 68 Ga-labeled agent for lesion detection was demonstrated across all PSA levels (o 0.5, 0.5-2.0 and 42.0 ng ml − 1 ). A particular interesting study was recently published in which 68 Ga-PSMA was compared with the 18 F-labeled PSMA ligand 18 F-DCFPyL 61 in patients with biochemical recurrence. Both radiotracers identified suspicious foci of abnormal radiotracer uptake suggesting sites of disease in 11 of 14 patients (79%). However, in three of the patients (21%), additional lesions were observed with 18 F-DCFPyL. Although the patient-level sensitivity of the radiotracers was identical, the additional lesions seen with 18 F-DCFPyL hints that the 18 F-labeled radiotracer may detect subtle sites of disease that would be missed by 68 Ga-PSMA, as described above based on the improved imaging characteristics of 18 F versus 68 Ga radionuclides for PET detection of smaller-sized lesions, potentially improving staging in the biochemically recurrent patient population.
As a confirmation of the superiority of PSMA-based PET to conventional cross-sectional imaging, a recent study directly comparing a 68 Ga-labeled PSMA radiotracer with three-dimensional volumetric CT in the evaluation of pelvic lymph nodes in patients with biochemically recurrent PCa demonstrated a superiority of PSMA-targeted PET to advanced CECT metrics, with twothirds of patients with lymph nodes identified by PET having been negative with CECT.
62
Evaluation and treatment planning in patients with widespread metastatic disease Although limited in the detection of biochemically recurrent PCa, CECT and BS can reliably detect widespread metastatic PCa. Nonetheless, PSMA-based PET has superior sensitivity in comparison with CECT and/or BS, either alone or in combination, for the detection of the sites of metastasis in both hormone-naive and castration-resistant metastatic PCa patients. 63 Even relative to the highly sensitive modality of Na 18 F PET/CT for the detection of osteoblastic bone metastases, PSMA-targeted PET/CT may identify more bone lesions in patients with widespread metastases. 64 Perhaps more important than this added sensitivity, the recent emergence of PSMA-targeted radiotherapeutics suggests that complete staging with diagnostic PSMA-based PET, of both soft tissue as well as bone metastases, may have an important role in the future treatment planning of patients with widely metastatic PCa, given that the total PSMA-ligand-avid tumor burden can inform the administered dose of radiotherapeutics.
Early studies on PSMA-based radiotherapy were carried out with a lutetium-177 ( 177 Lu)-labeled version of the J591 antibody ( 177 Lu is a beta-particle emitting radionuclide that also decays by single-photon emission and can be imaged with a gamma camera). In a phase I trial involving 35 patients with progressive . Subtle increased radiotracer uptake is seen in the right prostate bed (red arrowheads) compatible with local recurrence of disease (uptake in the urinary bladder is present anteromedial to the local recurrence). The patient subsequently underwent salvage radiotherapy with a boost to the region of 18 F-DCFPyL uptake and PSA level became undetectable. The lack of radiotracer uptake outside of the typical salvage pelvic radiation field increased the confidence level of the treating clinicians that salvage radiotherapy was the appropriate course of action in this patient. CT, computed tomography; PET, positron emission tomography.
castration-resistant metastatic PCa, Bander et al. 65 demonstrated that multiple doses of 177 Lu-J591 were well tolerated with reasonable toxicity and with radiotracer uptake at known sites of metastatic PCa. The follow-up phase II study with 177 Lu-J591 was carried out in 47 metastatic castration-resistant patients, with 59.6% of patients showing a decrease in serum PSA, although reversible myelosuppression was observed with a significant number of patients having grade 4 thrombocytopenia and/or neutropenia. 66 More recently, radiotherapeutic versions of small-molecule inhibitors of PSMA have also been reported. 177 Lu has also been the radiometal of choice for these agents, given that the same chelator moieties that can be conjugated to 68 Ga also generally have affinity for 177 Lu, allowing for combined diagnostic and therapeutic capabilities into a single agent or a theranostic PCa agent. Weineisen et al. 67 recently reported on an optimized ligand ('PSMA inhibitor for imaging and therapy', 'PSMA I&T') that could be labeled with both 68 Ga and 177 Lu; 68 Ga-PSMA I&T imaging demonstrated high tumor-to-background and 177 Lu-PSMA I&T was well tolerated in two patients with no detectable side effects. An additional small study of 10 patients who underwent imaging with 68 Ga-PSMA and were then treated with the radioligand 177 Lu-DKFZ-617 ('Lu-PSMA') was notable for a serum PSA decline in 70% of the patients, with five patients experiencing a decline of 450%.
68 Four patients had some degree of myelosuppression; however, the overall hematologic effects appear to be less than those observed with 177 Lu-J591. These early promising results obtained by imaging and then treating patients with radiotherapeutics targeting PSMA (that is, a 'theranostic' approach) certainly merit further study in larger patient cohorts. Caution must be exercised, however, as there is very high PSMA-targeted radiotracer uptake in the salivary glands and kidneys, and long-term toxicity to these organs may ultimately limit application of these new therapeutic agents.
GUIDING TARGETED THERAPY FOR OLIGOMETASTATIC DISEASE
In recent years, there has been increasing biological and clinical evidence for, and recognition of, an intermediate state of cancer that exists on a continuum between localized and widespread metastatic cancer. 69, 70 Often termed oligometastatic disease and generally defined as less than or equal to five metastatic sites, this state is believed to arise biologically as a result of cancer cells acquiring some, but not all, of the characteristics necessary for wide metastatic spread. In selected patients with certain malignancies, focally treating all the sites of oligometastatic disease may offer cure or long-term local control ( Figure 5 ; ref. 70) . Multiple clinical trials are currently underway to assess the best approach for the treatment of oligometastatic disease in PCa. 71 It follows that the more reliably an imaging modality is able to identify the sites of metastatic PCa, the more appropriately patients can be selected for the treatment of oligometastatic disease. Given the earlier discussions in this manuscript on the lack of sensitivity of CECT and BS for detecting the sites of metastatic PCa in pre-operative high-risk and biochemically recurrent patients, these conventional imaging modalities would be expected to significantly understage patients. As such, conventional imaging would suggest some patients have oligometastases when they actually harbor widespread metastatic disease or under represent the number of oligometastases. More sensitive molecular imaging methods such as PSMA PET offer the opportunity to at least partially address the current limitations in staging oligometastatic patients.
Suggestions of the role PSMA-directed therapy for oligometastatic PCa may play in the future have already begun to appear in the literature. For example, in the large retrospective trial of 68 Ga-PSMA in biochemical recurrence reported by Afshar-Oromieh et al., 21 it was noted that 50 out of 116 patients for whom followup was available had received local therapy at the sites of biochemical recurrence that were identified by the PSMA PET scan, instead of proceeding to immediate systemic therapy such as androgen deprivation. These focal therapies included external beam radiation, surgery and high-intensity focused ultrasound. Although some of these lesions were undoubtedly local recurrence and not metastases, per se, the ability of PSMA-targeted PET to guide such interventions is an important finding.
A more direct example of focal oligometastatic treatment guided by PSMA imaging was recently published. Schiavina et al. described a case of a patient with biochemical recurrence who underwent 68 Ga-PSMA PET/CT scanning and was found to have radiotracer-avid retroperitoneal adenopathy. 72 No other sites of disease were appreciated. Following salvage retroperitoneal lymph node dissection, the patient's PSA became undetectable. A larger-scale retrospective study by Hijazi and colleagues demonstrated that 68 Ga-PSMA PET could reliably identify oligometastatic lymph node involvement in patients who were treated with an extended pelvic lymph node dissection after biochemical recurrence or in high-risk PCa before prostatectomy. 73 CONCLUSIONS A large, and growing, literature has emerged in recent years demonstrating the potential utility of PSMA-based imaging of PCa for a variety of indications. To date, the most clear clinically indication is for patients with biochemical recurrence, with PSMAbased PET so far proving to have higher sensitivity than any other modality for localization of the site of recurrence, including other PET molecular imaging agents. Other applications that show promise include the characterization and risk stratification of primary PCa, complete staging of metastatic PCa to allow for PSMA-targeted radiotherapy and improved identification of patients with oligometastatic disease. Early results would indicate that pre-operative imaging for determination of pelvic lymph node involvement in high-risk primary PCa may be limited, although PSMA-based intraoperative guidance may ultimately prove valuable. In coming years, the onus is on our field, composed of a multi-disciplinary collaborative effort of imagers and treating physicians and surgeons, to carry out large and wellthought-out prospective trials to definitively uncover the true utility of PSMA-based PET to improve the management and outcomes of patients with PCa.
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